02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
11:05 , Apr 3, 2019 |  BC Extra  |  Financial News

Bigger bites, more digital health for HealthQuest's new $440M fund

With a new $440 million venture fund nearly double the size of its predecessor, HealthQuest Capital plans to take bigger stakes in its portfolio companies and grow its footprint in digital health. While the Bay...
23:12 , Apr 10, 2018 |  BC Extra  |  Company News

Management tracks: Immunomedics, argenx

Antibody company Immunomedics Inc. (NASDAQ:IMMU) hired Robert Iannone as CMO and head of R&D. He was SVP and head of immuno-oncology, global medicines development at AstraZeneca plc (LSE:AZN; NYSE:AZN). Antibody company argenx S.E. (Euronext:ARGX; NASDAQ:ARGX)...
23:54 , Jan 4, 2018 |  BC Extra  |  Company News

Management tracks: Acceleron, Selecta

Acceleron Pharma Inc. (NASDAQ:XLRN) said EVP and CMO Matthew Sherman will retire after the company reports top-line data mid-year from the Phase III MEDALIST and BELIEVE trials of luspatercept (ACE-536) to treat lower-risk myelodysplastic syndromes...
00:25 , Jun 21, 2017 |  BC Extra  |  Company News

Management tracks

Biogen Inc. (NASDAQ:BIIB) named Ginger Gregory EVP and chief human resources officer, effective July 17. She was chief human resources officer at Shire plc (LSE:SHP; NASDAQ:SHPG). Neurodegenerative, inflammation and cancer company Active Biotech AB (SSE:ACTI)...
20:02 , May 5, 2017 |  BC Week In Review  |  Financial News

Avedro raises $42M in venture and debt financings

On April 27, ophthalmic company Avedro Inc. (Waltham, Mass.) raised a combined $42 million across a venture financing led by HealthQuest Capital, with participation from existing investors OrbiMed Advisors and InterWest Partners , and a...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Financial News

Avedro completes venture financing

Avedro Inc. , Waltham, Mass.   Business: Ophthalmic   Date completed: 2015-11-13   Type: Venture financing   Raised: $32 million   Investors: InterWest Partners; OrbiMed Advisors; existing investors  ...
07:00 , Oct 26, 2015 |  BC Week In Review  |  Clinical News

Riboflavin ophthalmic solution regulatory update

Avedro resubmitted an NDA to FDA for riboflavin ophthalmic solution for use with the KXL System to treat progressive keratoconus or corneal ectasia following refractive surgery. The company expects a PDUFA date in April 2016....
07:00 , Apr 20, 2015 |  BC Week In Review  |  Clinical News

Riboflavin ophthalmic solution regulatory update

FDA issued a complete response letter to Avedro for an NDA for VibeX to treat progressive keratoconus or corneal ectasia following refractive surgery. The company said FDA requested more information, but that none of those...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Clinical News

Riboflavin ophthalmic solution regulatory update

FDA’s Dermatologic and Ophthalmic Drugs and Ophthalmic Devices Panel of the Medical Devices advisory committees voted in support of approval of Avedro’s riboflavin ophthalmic solution with UVA irradiation. The product is under review for use...